Expression of epidermal growth factor receptor (EGFR) in systemic sclerosis patients (SSc) and gastro-oesophageal reflux disease (GORD)
Copyright © 2023 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved..
INTRODUCTION: Systemic sclerosis (SSc) affects the connective tissue and leads to an abnormal fibrotic process in the skin and internal organs. Epidermal Growth Factor Receptor (EGFR) is able to induce cell proliferation and differentiation, and its expression is increased in SSc patients with pulmonary artery hypertension and in skin biopsies in patients with scleroderma. To date, no data on esophageal expression of EGFR are available in SSc patients. We aimed to evaluate whether the pro-fibrogenic pathways of SSc may affect EGFR expression in the esophagus.
METHODS: A retrospective analysis included patients with SSc and control subjects suffering from gastroesophageal reflux symptoms. Endoscopic assessment and histopathologic analyses were performed in all subjects and the presence of microscopic esophagitis was used to distinguish patients with normal esophageal mucosa and subjects with non-erosive reflux disease. EGFR expression was measured in all subjects.
RESULTS: A total of 35 patients with SSc were included, while the control group included 67 non-SSc patients. EGFR expression at the Z-line was higher in SSc patients than non-SSc patients in absence of microscopic esophagitis (median 65 %, IQR 56-71 % vs 42 %, IQR 37-54 %, p < 0.001). Microscopic esophagitis was found in 60 % of patients with SSc and 62.7 % of control patients, and EGFR expression was significantly higher in patients presenting microscopic esophagitis both in SSc and non-SSc patients.
CONCLUSION: The EGFR hyperexpression may be due to SSc and/or reflux-related damage in patients with microscopic esophagitis. Further studies are warranted to answer open questions and provide a possible role of EGFR in terms of diagnosis, prognosis, and therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:265 |
|---|---|
| Enthalten in: |
Immunology letters - 265(2024) vom: 15. Feb., Seite 31-36 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pasta, Andrea [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EC 2.7.10.1 |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.imlet.2023.106834 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366620878 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366620878 | ||
| 003 | DE-627 | ||
| 005 | 20240214233046.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.imlet.2023.106834 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM366620878 | ||
| 035 | |a (NLM)38171474 | ||
| 035 | |a (PII)S0165-2478(23)00205-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pasta, Andrea |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Expression of epidermal growth factor receptor (EGFR) in systemic sclerosis patients (SSc) and gastro-oesophageal reflux disease (GORD) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a INTRODUCTION: Systemic sclerosis (SSc) affects the connective tissue and leads to an abnormal fibrotic process in the skin and internal organs. Epidermal Growth Factor Receptor (EGFR) is able to induce cell proliferation and differentiation, and its expression is increased in SSc patients with pulmonary artery hypertension and in skin biopsies in patients with scleroderma. To date, no data on esophageal expression of EGFR are available in SSc patients. We aimed to evaluate whether the pro-fibrogenic pathways of SSc may affect EGFR expression in the esophagus | ||
| 520 | |a METHODS: A retrospective analysis included patients with SSc and control subjects suffering from gastroesophageal reflux symptoms. Endoscopic assessment and histopathologic analyses were performed in all subjects and the presence of microscopic esophagitis was used to distinguish patients with normal esophageal mucosa and subjects with non-erosive reflux disease. EGFR expression was measured in all subjects | ||
| 520 | |a RESULTS: A total of 35 patients with SSc were included, while the control group included 67 non-SSc patients. EGFR expression at the Z-line was higher in SSc patients than non-SSc patients in absence of microscopic esophagitis (median 65 %, IQR 56-71 % vs 42 %, IQR 37-54 %, p < 0.001). Microscopic esophagitis was found in 60 % of patients with SSc and 62.7 % of control patients, and EGFR expression was significantly higher in patients presenting microscopic esophagitis both in SSc and non-SSc patients | ||
| 520 | |a CONCLUSION: The EGFR hyperexpression may be due to SSc and/or reflux-related damage in patients with microscopic esophagitis. Further studies are warranted to answer open questions and provide a possible role of EGFR in terms of diagnosis, prognosis, and therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Epidermal growth factor receptor | |
| 650 | 4 | |a Gastroesophageal reflux disease | |
| 650 | 4 | |a Microscopic esophagitis | |
| 650 | 4 | |a Systemic sclerosis | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a EGFR protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Calabrese, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Djahandideh Sheijani, Shirin |e verfasserin |4 aut | |
| 700 | 1 | |a Furnari, Manuele |e verfasserin |4 aut | |
| 700 | 1 | |a Giannini, Edoardo G |e verfasserin |4 aut | |
| 700 | 1 | |a Grillo, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Marabotto, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Mastracci, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Murdaca, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Negrini, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Savarino, Edoardo Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Savarino, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Zentilin, Patrizia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Immunology letters |d 1983 |g 265(2024) vom: 15. Feb., Seite 31-36 |w (DE-627)NLM012603953 |x 1879-0542 |7 nnns |
| 773 | 1 | 8 | |g volume:265 |g year:2024 |g day:15 |g month:02 |g pages:31-36 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.imlet.2023.106834 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 265 |j 2024 |b 15 |c 02 |h 31-36 | ||